Trim 25-30% at spot + buy $360 put protection; reject new short, reassess at Oct 13 Q3 earnings
Structural bear case wins directionally: confirmed downtrend (five lower highs and four lower lows in 75 trading days), MACD bearish non-divergence, intact 50 SMA resistance ($393, 10+ weeks of rejection), and structural margin compression (6.2% in 2021-2023 to 2.7% in 2025). Macro headwinds include 10Y at multi-decade highs with 97% implied probability of zero 2026 cuts. Underweight at initiation is the correct response per the 09-30 binding reflection, not Hold as a fallback after alpha bleeds. Trim 25-30% at spot (heavier than 09-28's 15-20% due to worsened momentum: MACD -7+ vs -6.04), plus $360 put hedge for residual. Rejecting new short position due to: concentrated event risk into binary catalyst, trim zone failure mode requiring price cooperation, and poor R/R (stop essentially at current spot risking ~$0 to make $17). Pre-defined reentry plan eliminates decision paralysis at catalyst.
| Position | Action |
|---|---|
| Execute immediately at current spot ($365-375 range) | Trim 25-30% of current UNH exposure |
| Hedge residual exposure post-trim | Buy $360 strike puts, October expiry (estimated cost 2-3% of position value) |
| Daily close below $351 | Exit remainder of position |
| Intraday break of $351 on volume >10M shares | Exit remainder of position |
| Weekly close below $349.61 | Full exit trigger |
The tape is a lagging indicator of business reality, and the business reality for UNH is inflecting hard to the upside—H1 2026 generated more free cash flow than all of 2025, the company is aggressively deleveraging and resuming buybacks, and forward P/E of 16.15x discounts an already-recovering earnings power that the stock hasn't yet reflected.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 352.37 | bullish |
| 50 SMA | 393.00 | bearish |
| 10 EMA | 373.34 | bearish |
| 20 SMA (Bollinger Middle) | 379.51 | neutral |
| Bollinger Lower Band | 360.49 | neutral |
| RSI | 33.18 | bearish |
| MACD | -6.67 | bearish |
| MACD Signal | -6.28 | bearish |
| MACD Histogram | -0.39 | bearish |
| ATR (14) | 8.68 | neutral |
| VWMA | 375.14 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Q3 print beats expectations, constructive FY26 guide, price holds $351 200 SMA
Then: Reload to neutral weight; target $393 (50 SMA), then $420
Q4 2025 was an anomaly quarter (Q4 2025 EPS $0.01, −99.6% sequential drop due to cyberattack and Change Healthcare charges), and Q1+Q2 2026 EPS annualized at ~$26 implies a forward P/E of 16.15x versus TTM P/E of 23.47x—45%+ earnings rebound already in consensus model but stock hasn't followed.
EV: +7.6% (Target 1: $393, 50 SMA); +15.0% (Target 2: $420, recovery high)
The structural picture is much worse than the cyclical recovery being priced in. The tape shows lower highs, lower lows, multiple compression, margin compression, regulatory escalation, news silence, and a binary test of the 200 SMA at $352 that carries more downside than upside skew.
· concedes: Q4 2025 EPS collapse of $0.01 was severe and recovery to $6.90 and $6.04 in Q1-Q2 2026 is real recovery; ATR compression does resolve in either direction — the coiled spring setup is technically valid, just not confirmed; Forward P/E of 16.2x is below historical ranges — the stock is not expensive by historical standards; The 200 SMA at $352 is a meaningful long-term support level and could hold; If the stock makes a new price low while MACD does NOT make a new low, a bullish divergence would confirm; Q3 2026 Polymarket at 78% beat probability reflects some genuine bullish expectation in the market
→ vs conservative: 200 SMA at $352 is a lagging indicator; by the time it breaks and 'confirmed close below' triggers action, half the year's gains are already gone—riding a 15-20% air pocket is not risk management, it's paralysis
→ vs conservative: Missing the asymmetry entirely: if they beat by a dime and guide flat, the stock rips lower, not higher—beat probability is not the same as positive reaction probability
→ vs neutral: 78% Polymarket probability is on $32 of trading volume—this is noise, not a conviction signal, and treating it as a green light ignores the actual asymmetry of the reaction
→ vs neutral: Forward P/E of 16.2x is anchored on consensus estimates working from a recovery thesis; if Q3 print doesn't validate, estimates get cut and 16.2x becomes 18-19x on lower denominators, stock trades down even if multiple holds
→ vs neutral: Silent news flow for a $500B mega-cap is not a comfort signal—it's a coiled spring; ATR compression to 8.68 means volatility expansion is overdue into a binary catalyst with thin liquidity in prediction markets
→ vs neutral: 'Quality defensive' framing is dangerous in this macro regime—defensives don't print 5 lower highs in 75 days or lose 20% from peak; this is a high-quality name in structural transition, not a stock to hug through turbulence
| bearish |
Support: 360.49 · 352.37 · 350 | Resistance: 373.34 · 379.51 · 393 · 398.53
Short-term and intermediate trends are bearish with price below all key moving averages and RSI approaching oversold territory at 33.18. The MACD histogram turned negative on September 22 and remains negative, confirming downside momentum. Bollinger Bands show price probing the lower band at 360.49, while ATR is compressing at 8.68, suggesting a volatility expansion event is likely near. The long-term trend remains intact above the rising 200 SMA at 352.37, but this level represents the critical line in the sand for bullish thesis maintenance. The final transaction proposal is HOLD.
Market Cap
$327.8B
Current Price
~$362
P/E (TTM)
23.47x
Forward P/E
16.15x
PEG Ratio
1.0
P/B
3.36x
EV/EBITDA
~13.9x
Dividend Yield
2.53%
Beta
0.62
52-Week High
$461.62
52-Week Low
$255.97
50-Day MA
$396.10
200-Day MA
$356.08
Revenue (TTM)
$450.5B
Gross Profit (TTM)
$88.9B
EBITDA (TTM)
$26.7B
Net Income (TTM)
$14.1B
Net Margin
3.13%
Operating Margin
7.13%
ROE
14.15%
ROA
4.87%
Total Debt
$73.3B
Net Debt
$44.7B
Cash
$28.6B
Stockholders' Equity
$98.4B
Goodwill
$110.6B
FCF (TTM)
$24.3B
Operating CF (TTM)
~$32B
Q2'26 Revenue
$112.0B
Q2'26 EPS
$6.04
Q2'26 Net Income
$5.48B
Q4'25 EPS
$0.01
Q1 2026 Revenue
$111.7B
Q1 2026 EPS
$6.90
Q1 2026 Net Income
$6.28B
Q4 2025 Revenue
$113.2B
Q4 2025 Net Income
$0.01B
Q3 2025 Revenue
$113.2B
Q3 2025 Net Income
$2.35B
Q2 2025 Revenue
$111.6B
Q2 2025 Net Income
$3.41B
2025 Revenue
$447.6B
2025 YoY Revenue Growth
+11.8%
2025 Net Income
$12.1B
2025 EPS
$13.23
2025 Net Margin
2.7%
2024 Revenue
$400.3B
2024 YoY Revenue Growth
+7.7%
2024 Net Income
$14.4B
2024 EPS
$15.51
2024 Net Margin
3.6%
2023 Revenue
$371.6B
2023 YoY Revenue Growth
+14.6%
2023 Net Income
$22.4B
2023 EPS
$23.86
2023 Net Margin
6.0%
2022 Revenue
$324.2B
2022 YoY Revenue Growth
0.0%
2022 Net Income
$20.1B
2022 EPS
$21.18
2021 Revenue
$324.2B
2021 Net Income
$20.1B
2021 EPS
$21.18
2021 Net Margin
6.2%
2025 Operating CF
$19.7B
2025 FCF
$16.1B
2024 Operating CF
$24.2B
2024 FCF
$20.7B
2023 Operating CF
$29.1B
2023 FCF
$25.7B
2022 Operating CF
$26.2B
2022 FCF
$23.4B
2021 Operating CF
$26.2B
2021 FCF
$23.4B
H1 2026 Operating CF
$19.96B
H1 2026 FCF
$18.40B
Q2 2026 Operating CF
$11.05B
Q2 2026 FCF
$10.25B
Q1 2026 Operating CF
$8.91B
Q1 2026 FCF
$8.15B
2025 Dividends Paid
$7.9B
2024 Dividends Paid
$7.5B
2025 Buybacks
$5.5B
2024 Buybacks
$9.0B
Total Capital Returned 2025
$13.4B
Total Capital Returned 2024
$16.5B
Shares Outstanding Q2 2026
905M
Shares Outstanding 2025
905.8M
2025 Debt
$78.4B
2024 Debt
$76.9B
2025 Net Debt
$54.0B
2024 Net Debt
$51.6B
2025 Stockholders' Equity
$94.1B
2024 Stockholders' Equity
$92.7B
2025 Goodwill
$131.0B
2025 Total Assets
$309.6B
2025 Total Liabilities
$207.9B
Working Capital Q2 2026
-$25.0B
Current Ratio Q2 2026
0.79
Interest Coverage
~10x
Debt/Equity
0.78x
Receivables Q2 2026
$46.3B
Tangible Book Value
-$36.9B
Forward EPS
$22.61
Expected EPS Rebound
~45%
2021→2025 Revenue CAGR
~8.4%
2021→2025 EPS CAGR
~-11%
H1'26 FCF vs FY2025
$18.4B vs $16.1B
Q2 2026 Buybacks
$1.65B
Q2 2026 Dividends
$2.09B
Q1 2026 Dividends
$2.00B
Q2 2026 Debt Repaid
$3.31B
Q1 2026 Debt Repaid
$1.50B
H1 2026 Debt Repaid
$4.81B
Annualized Dividend Q2 2026
~$8.3-8.4B
Shareholder Yield
~4.6%
2025 CapEx
$3.6B
2024 CapEx
$3.5B
2025 Acquisitions
$4.5B
2024 Acquisitions
$13.4B
Strengths
Concerns
UNH fundamentals show a clear earnings and cash flow recovery after difficult 2024-2025. Revenue is remarkably stable at ~$112B/quarter ($450.5B TTM), but net margin compressed to 3.13% (vs ~6% historically) due to Q4 2025 anomaly when net income collapsed to just $10M. Q1-Q2 2026 show sharp recovery with EPS more than doubling from Q4'25 trough. H1 2026 FCF of $18.4B already exceeds full-year 2025 FCF of $16.1B, enabling net debt reduction of $9.3B to $44.7B. The valuation disconnect between TTM P/E (23.47x) and Forward P/E (16.15x) signals strong expected earnings recovery (~45% to $22.61), while the stock trades ~$100 below its 52-week high of $461.62, offering attractive risk/reward for a quality compounder with defensive characteristics.
Macro: Hawkish Fed regime dominates with 97% odds of no rate cuts in 2026 and 10-year Treasury yields at multi-decade highs (highest since 2002, September posting the biggest monthly gain since 2022). Fed officials reinforcing 'inflation still too high' messaging on September 30/October 1. US recession odds at 8% (down 2 percentage points on the week), supporting soft-landing consensus that mutes the defensive bid for quality names like UNH. Oct 1 saw a modest relief rally as yields pulled back from extremes, with Dow/S&P/Nasdaq rallying and chip/consulting stocks leading. The higher-for-longer rate environment is a net negative for UNH via multiple compression and elevated MLR pressure from sticky-wage healthcare services, partially offset by investment-income tailwind on premium float.